Fierce Pharma
SEPTEMBER 30, 2024
After experiencing a series of ups and downs in recent years, the biopharma contracting business is gearing up for a rebound in 2025. | Ahead of the CPHI conference in Milan, the events group has teased new research signaling an expected rebound for the CDMO industry—and a rejection of the BIOSECURE Act.
MedCity News
SEPTEMBER 30, 2024
Memorial Hermann Health System and Moffitt Cancer Center have recently struck partnerships with Reimagine Care, a startup focused on providing support to cancer patients via an AI assistant and text messages with oncology experts. The post Health Systems Are Partnering with Reimagine Care to Improve Cancer Treatment appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
SEPTEMBER 30, 2024
After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson & Johnson and Legend Biotech’ Carvykti has once again mounted a maj | After putting on a strong performance in preventing disease progression, Johnson & Johnson and Legend Biotech’s Carvykti has once again demonstrated a major benefit—this time in prolonging patients’ lives.
MedCity News
SEPTEMBER 30, 2024
By embracing available data, cutting-edge technology, and an intelligent marketplace, payers can design solutions that optimize costs across the entire healthcare ecosystem. The post Payers Possess the Tools to Tackle Rising Healthcare Costs appeared first on MedCity News.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Fierce Pharma
SEPTEMBER 30, 2024
With its first approval in hand, privately held IntraBio is embarking upon the difficult task of marketing a drug for an ultra-rare disease. | With its first approval in hand, privately held IntraBio is embarking upon the difficult task of marketing a drug for an ultra-rare disease. Still, with months of prep work and outreach complete, the company is already proving it can hit the ground running.
PharmaVoice
SEPTEMBER 30, 2024
The company’s allogeneic therapy was OK’d in the EU and could become the first of its kind approved by the FDA in January — while eyeing the next frontier.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
SEPTEMBER 30, 2024
In this month’s episode, Senior Reporter Katie Adams explored some of the executive moves, exits and layoffs that recently occurred in the healthcare sector. She also interviewed Dr. Jayne Morgan, who recently became vice president of medical affairs at Hello Heart. The post MedCity Moves Podcast: Recent Hires, Layoffs & an Interview with Dr. Jayne Morgan, VP of Medical Affairs at Hello Heart appeared first on MedCity News.
Pharmaceutical Commerce
SEPTEMBER 30, 2024
Why looming benefit changes—and the resulting unintended consequences—are a concern for patients.
MedCity News
SEPTEMBER 30, 2024
Healthy Young Minds is an online youth mental health startup. It was recently crowned winner of MedCity News’ INVEST Pitch Perfect contest focused on pediatric mental health. The post INVEST Pitch Perfect Spotlight: How One Startup Aims To Become the Leading Medicaid Mental Health Provider for Kids appeared first on MedCity News.
pharmaphorum
SEPTEMBER 30, 2024
Chiesi Biotech Center of Excellence opens to strengthen R&D in Italy Nicole.
MedCity News
SEPTEMBER 30, 2024
Bristol Myers Squibb is turning to the prime-editing technology of Prime Medicines for the R&D of new cell therapies for cancer and immunology. The pharma giant is paying $110 million up front to begin the collaboration. The post Gene-Editing Biotech Prime Medicine Strikes Up Cell Therapy R&D Alliance With Bristol Myers Squibb appeared first on MedCity News.
Pharmaceutical Technology
SEPTEMBER 30, 2024
The retrospective study presented at ESMO 2024 involved about 2,400 patients with stage 3 or 4 non-small cell lung cancer.
Pharmaceutical Commerce
SEPTEMBER 30, 2024
Steve Silvestro explains the value of artificial intelligence in launch plans, benefits to integrating DTC and HCP marketing strategies, and more.
Pharmaceutical Technology
SEPTEMBER 30, 2024
Medidata is a winner in the Innovation, and Product Launches categories in the 2024 Pharmaceutical Technology Excellence Awards.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
PharmaTech
SEPTEMBER 30, 2024
In vitro transcription (IVT) is often used to make mRNA, and in co-transcriptional capping an analog cap can be used to cap the mRNA. This paper reviews the recent history of capping analogs in addition to a state-of-the-art approach to improve protein expression.
Healthcare Success
SEPTEMBER 30, 2024
Managing successful Google Ads campaigns is more than just winning clicks—it’s about converting those clicks into results (e.g., new patients or B2B inquiries). At Healthcare Success, we manage millions of dollars in Google Ads spend for our healthcare clients. We often see the following 13 mistakes tank conversion rates. But don’t worry—13 isn’t unlucky here.
PharmaTech
SEPTEMBER 30, 2024
This Behind the Headlines news roundup panel discussion discusses news items such as research results from the June Lab at the University of Pennsylvania presented at the Hanson Wade 9th CAR-TCR Summit; winter vaccine recommendations, particularly for respiratory syncytial virus (RSV) and Beyfortus access and deployment; upcoming early October Nobel prize announcement predictions; digital biology analytics, quantitation, alongside point of care (POC) and distributed manufacturing.
Pharmaceutical Commerce
SEPTEMBER 30, 2024
In the second part of his interview with Pharma Commerce Editor Nicholas Saraceno, Gautam Prem Jain, GoComet’s Co-founder and CEO, explains the sales and operations planning (SO&P) process that can help create logistical efficiencies.
PharmaTech
SEPTEMBER 30, 2024
The company is touting its HPC74 series, which it said features heat-seal coated construction and has the highest puncture and tear strength of all of its reinforced medical papers to date.
PharmExec
SEPTEMBER 30, 2024
In this part of his Pharmaceutical Executive video interview, Jonathan Scheinberg, of the Northeast Science and Technology Center, discusses what specific areas of research and development are likely to benefit the most from this influx of of venture capital and federal funding.
European Pharmaceutical Review
SEPTEMBER 30, 2024
177 Lu-Dotatate has shown potential for extending progression-free survival for patients with the brain cancer meningioma, with results showing more favourable improvements compared to historical benchmarks. The Phase II clinical trial investigated whether refractory meningioma can be treated with theranostics. This treatment approach uses radiopharmaceuticals and provides patients with potentially a more effective treatment option, the researchers explained.
PM360
SEPTEMBER 30, 2024
Digital disruption in the pharma sector is being slowed down by budget constraints, and that does not seem like it’s going to change any time soon, according to new research from digital experience agency Graphite Digital. The Disconnected Pharma report reveals pharma companies are keen on strengthening their digital capabilities and offerings, setting a foundation for them to build upon as their customers’ needs change and new technologies emerge. 37 percent of pharma leaders want to ensure tha
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharmaceutical Technology
SEPTEMBER 30, 2024
LEO Pharma has submitted a New Drug Application (NDA) to China's National Medical Products Administration for Enstilar, targeting the treatment of adult patients with plaque psoriasis.
PM360
SEPTEMBER 30, 2024
PM360 Q&A WITH FRANK BURREL CEO Deerfield Group Frank Burrell is CEO of Deerfield Group, bringing more than 20 years of agency and client experience to implement marketing strategies across multiple therapeutic categories for specialty and retail products. Frank works as a valued partner to provide comprehensive marketing solutions that not only drive revenue but can be easily integrated within a company’s infrastructure.
Pharmaceutical Technology
SEPTEMBER 30, 2024
SK pharmteco, a contract development and manufacturing organisation, has announced an investment of $260m to expand its small molecule and peptide production capabilities.
PM360
SEPTEMBER 30, 2024
for Your Brand, Company, or the Industry as a Whole Building trust equity in the pharmaceutical industry hinges on a commitment to transparency, reliability, and ethical practices. Engaging with healthcare professionals and patients through educational initiatives and open dialogue helps to demystify complex information and foster a sense of reliability between the two.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
SEPTEMBER 30, 2024
The first needle-free epinephrine nasal spray, Neffy by ARS Pharmaceuticals, represents a significant breakthrough in emergency treatment for type I allergic reactions.
PM360
SEPTEMBER 30, 2024
Shaker Spotlight JENNIFER JOE APPOINTED VICE PRESIDENT OF MEDICAL AFFAIRS AT DIALITY Jennifer Joe, MD, former Senior Director of Global Medical Strategy & Population Health at AstraZeneca, has been appointed Vice President of Medical Affairs at Diality. Joe is a nephrologist who graduated from the Harvardaffiliated Massachusetts General Hospital and Brigham and Women’s Hospital.
PharmExec
SEPTEMBER 30, 2024
Flyrcado is the first positron emission tomography myocardial perfusion imaging agent of its kind designed for the detection of coronary artery disease.
PM360
SEPTEMBER 30, 2024
We caught up with Fred Hassan, founder of Sparkle of Hope, which has now become the largest annual gathering of the biopharmaceutical industry in Northern New Jersey. Fred founded the Sparkle of Hope in 1998. He says it was founded on the belief that many gaps in mental health support, and especially support for veterans, could be mitigated by the involvement of biopharmaceutical companies.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Expert insights. Personalized for you.
299 
Let's personalize your content